Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613 is registered in ClinicalTrials.gov with Context Therapeutics Inc. as lead sponsor.

NCT NCT06515613
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06515613 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Lead sponsor
Context Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
July 10, 2024
Completion date
December 31, 2028
Enrollment
156 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, platinum-resistant ovarian cancer, testicular cancer